MAR Research Update — September 17, 2026
Updated Thesis
Marriott International is a global asset-light hotel franchisor and manager whose 10,082-property, 1.814 million-room system, 629,000-room development pipeline, broad brands, and more than 295 million Bonvoy members support durable fee-led economics. Business quality is tempered by cyclicality, competitive owner incentives, and $16.915 billion of debt, while reported ROE is negative 66.7%. In the most recent quarter, revenue grew 4.8% year over year and earnings grew 0.4%, while worldwide RevPAR increased 3.4% and net fee revenue rose 13%.
The investment grade as of this refresh is C — average business quality. Medium-tier business, expensive-tier valuation, with 20.6% upside to $403.81 fair value offset by high leverage, cyclical international exposure, and modest recent-quarter earnings growth.
Key Metrics at a Glance
- Revenue growth: +4.8% year over year
- Net margin: 9.6%
- Fair value upside: +20.6% to our estimate of $404
Current price: $334.97
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Marriott International, Inc. remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full MAR research →](/stocks/MAR)